Archives
Please, enter cell line, author or any other phrase or word you would like to search for.
Prostate Cancer Research in Movember
Globally, prostate cancer is the second most commonly occurring cancer in men and the fourth most commonly occurring cancer overall. This video shows Etoposide treated DU 145 prostate cancer cells undergoing programed cell death, apoptosis.
Dissertation: A study of Cancer Cells by Digital Holographic Imaging
Sofia Kamlund has studied Cell Division and Cell Movement using Digital Holographic Microscopy. Her research presents new ways of analyzing individual cells by using Holographic Microscopy alone or in combination with Fluorescence Microscopy.
PHI HoloMonitor User Meeting
PHI had a successful Holomonitor User Meeting where we discussed how to use HoloMonitor with focus on cancer research. The presentations showed new methods within cancer research and cell biology.
Best Poster Prize to Louise Sternbaeck
PHI’s Industrial Doctoral Student Louise Stenbaeck received a prize from Danish Cancer Society for her poster “Holographic microscopy: Macrophage-uptake of SA-MIPs”.
TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression
Rights issue enables market expansion
The Board of Directors and the CEO of Phase Holographic Imaging PHI AB (publ), corporate identity number 556542-7811, hereby submit Interim Report 1 for the fiscal year 2018/19.
Digital Holographic Microscopy for biomarker detection in cancer
“In the near future”, Zahra El-Schich says, “you could have a HoloMonitor in every clinic. You could also customize cancer treatment for every patient by just using a simple tumor test.” Find out how.
Kallelse till årsstämma i Phase Holographic Imaging PHI (publ)
Aktieägarna i Phase Holographic Imaging PHI AB (publ), 556542-7811, kallas härmed till årsstämma onsdagen den 26 september 2018 kl. 17.00 i bolagets lokaler, Scheelevägen 22 i Lund.
New CEO commentary: “Understanding Skin Cancer”
PHI’s CEO and founder Peter Egelberg comments the latest research results by the scientists at the PHI/UCSF Holographic Imaging Cytometry Center of Excellence.
Scientists at UCSF-PHI Center of Excellence map the genetic progression of invasive skin cancer
Utilizing precision genetic engineering and PHI’s HoloMonitor technology, scientists at University of California, San Francisco, have for the first time been able to monitor and map how mutations break down the genetic protection against skin cancer.